Literature DB >> 20662349

Elevated plasma levels of apelin in children with type 1 diabetes mellitus.

Cihan Meral1, Emre Tascilar, Ferhan Karademir, Ilhan Asya Tanju, Ferhat Cekmez, Osman Metin Ipcioglu, Cemal Nuri Ercin, Ismail Gocmen, Teoman Dogru.   

Abstract

BACKGROUND: Apelin is a novel adipocytokine produced by white adipose tissue that binds the APJ receptor with high affinity. Insulin may have a role in regulation of apelin synthesis and secretion from the adipose tissue.
OBJECTIVE: To investigate blood apelin concentrations in children with type 1 diabetes mellitus (T1DM) and display association of apelin with adiponectin, body mass index (BMI), lipids and insulin sensitivity.
METHODS: Thirty patients with T1DM and 45 healthy controls were enrolled. Apelin levels were measured along with BMI, lipids, fasting plasma glucose, HbA1c and adiponectin levels.
RESULTS: Plasma apelin and adiponectin levels were significantly higher in the diabetic group when compared to controls. No correlation was found between the apelin blood concentrations and adiponectin, BMI, lipids and insulin sensitivity.
CONCLUSIONS: Children with T1DM have significantly increased circulating apelin levels when compared to healthy controls. However, no significant relation was found between the apelin and BMI, glucose, lipids and adiponectin levels, and also insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662349     DOI: 10.1515/jpem.2010.081

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  8 in total

Review 1.  Apelin, diabetes, and obesity.

Authors:  Isabelle Castan-Laurell; Cédric Dray; Camille Attané; Thibaut Duparc; Claude Knauf; Philippe Valet
Journal:  Endocrine       Date:  2011-08       Impact factor: 3.633

2.  Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.

Authors:  Patrick R Maloney; Pasha Khan; Michael Hedrick; Palak Gosalia; Monika Milewski; Linda Li; Gregory P Roth; Eduard Sergienko; Eigo Suyama; Eliot Sugarman; Kevin Nguyen; Alka Mehta; Stefan Vasile; Ying Su; Derek Stonich; Hung Nguyen; Fu-Yue Zeng; Arianna Mangravita Novo; Michael Vicchiarelli; Jena Diwan; Thomas D Y Chung; Layton H Smith; Anthony B Pinkerton
Journal:  Bioorg Med Chem Lett       Date:  2012-09-07       Impact factor: 2.823

3.  Apelin retards the progression of diabetic nephropathy.

Authors:  Robert T Day; Rita C Cavaglieri; Denis Feliers
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-09

4.  Adiponectin is a Good Marker for Metabolic State among Type 1 Diabetes Mellitus Patients.

Authors:  Hamdollah Karamifar; Narges Habibian; Gholamhosein Amirhakimi; Zohre Karamizadeh; Abbas Alipour
Journal:  Iran J Pediatr       Date:  2013-06       Impact factor: 0.364

5.  Apelin, Nitric Oxide and Vascular Affection in Adolescent Type 1 Diabetic Patients.

Authors:  Soha M Abd El Dayem; Ahmed A Battah; Abo El Maged El Bohy; Rash Nazih Yousef; Azza M Ahmed; Ahmed A Talaat
Journal:  Open Access Maced J Med Sci       Date:  2017-12-04

6.  The Effect of Aerobic Exercise Training on Plasma Apelin Levels and Pain Threshold in T1DM Rats.

Authors:  Reza Delavar; Ali Heidarianpour
Journal:  Iran Red Crescent Med J       Date:  2016-05-11       Impact factor: 0.611

7.  Apelin and chemerin as promising adipokines in children with type 1 diabetes mellitus.

Authors:  Asmaa Abd El Wakeel Elsehmawy; Safinaz Ebrahim El-Toukhy; Nora Mohamed Ahmed Seliem; Rehab Selim Moustafa; Doaa Sayed Mohammed
Journal:  Diabetes Metab Syndr Obes       Date:  2019-03-22       Impact factor: 3.168

8.  Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus.

Authors:  Maria Gisella Cavallo; Federica Sentinelli; Ilaria Barchetta; Carmine Costantino; Michela Incani; Laura Perra; Danila Capoccia; Stefano Romeo; Efisio Cossu; Frida Leonetti; Luciano Agati; Marco G Baroni
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.